PPAR-γ配体RGZ对胆管癌移植瘤抗肿瘤活性的实验研究

Experimental Study on Antitumor Activity of PPAR-ligand RGZ in Cholangiocarcinoma Xenografts

目的探讨PPAR-γ配体罗格列酮(rosiglitazone,RGZ)对胆管癌移植瘤的抗肿瘤活性。方法采用不同浓度和剂量的RGZ对荷瘤裸小鼠进行灌胃干预3W后处死,测量各组瘤体体积和重量,计算相对肿瘤体积、相对肿瘤增值率T/C%;RT-PCR检测PPAR-"的表达,Tunel检测凋亡,SP法检测CD34的表达并计算MVD,进行统计学分析。结果胆管癌移植瘤随RGZ剂量增高,PPAR-γ的表达升高,凋亡率增高,瘤体体积和重量减少,相对肿瘤增值率T/C%减少,CD34表达降低,MVD密度降低。对照组与低剂量组比较差异无统计学意义(P>0.05);而与高剂量组比较差异有统计学意义(P<0.01)。结论 10倍以上剂量RGZ对胆管癌移植瘤有明显的增值抑制作用和较好的抗肿瘤活性。

Objective To investigate the antitumor activity of PPAR-γ（ rosiglitazone, RGZ） on cholangiocarcinoma xenografts. Methods The nude mice heating tumor weresacrificed 3W aftersubjected to intragasttic intervention by RGZ with different concentration and dose. The volume and weight of tumorwere measured in all groups, and the relative tumor volume and relative tumor appreciation rate T/C% were calculated. RT-PCR was used to detect the expression of PPAR-γ. Tunel was used to detect ap- optosis. The expression of CD34 was detected by SP and MVD was calculated, and statistical analysis was performed. Results With the increase of RGZ dose, the expression of PPAR-γ increased, the apoptosis rate increased, the volume and weight of tumor decreased, the relative tumor appreciation rate T/C% decreased, the expression of CD34 decreased, and the density of MVD decreased. Statistical treatment, compared with the lowdose group, there was no statistical significance in the control group （ P 〉 0.05 ）. However, compared with the high dose group, there was obvious significant statistical significance（P 〈 0. 001 ）. Conclusion RGZ has significant inhibitory effect on the proliferation of cholangiocarcinoma in 10 times more than the human body, and has good anti-tumor activity.